CancerPathology

Digital pathology/ai as a strategy to determine the pathogenesis of multiple chemical sensitivity: a proposal to demystify a problematic puzzle of pathology

Presented in Emirates Pathology, Digital Pathology & Cancer Conference Holiday Inn Dubai, Al Barsha, UAE & Virtual
Poster Presenter Name: Dr. Zev Leifer
Research interest:
Gene Regulation. Pathology Education.
Global Journal of Pathology & Laboratory Medicine

Unified Citation Journals, Pathology 2024, ISSN 2754-0952

Biography: 

Dr. Zev Leifer has a Master’s Degree in Medical Sciences from Harvard University. He has a Ph.D. from New York University in Microbiology. He was on the faculty of New York Medical College for six years and, for the past 37 years, has been Professor of Microbiology and Pathology at the New York College of Podiatric Medicine. He taught Pathology Lab, as an all-digital course as the field developed in that direction. He founded The Leifer Institute for Molecular and Digital Pathology,

His research interests involve factors affecting genetic regulation. On the pathology side, he is focused in the training of undergraduate students in the use of the new digital technology. An MCS patient personally known has triggered a great interest in working towards a treatment for this condition.

Introduction: Multiple Chemical Sensitivity (MCS) is a multisystem recurrent disorder that presents in response to different exposures to environmental chemicals and other stimuli at lower concentration and at greater intensity than characteristic of previous or general experience. Following an initiation by a high concentration or long-term exposure the patient is then subject to a triggering effect of multiple and even different chemicals. They are often volatile organic chemicals found in the home or workplace. As a result, the patient often cannot remain safely at home or at work and must have a “safe space” or a “safe location”. Symptoms can present at the Immunological, Respiratory, Neurological and/or Dermatological level.

Much effort is being expended to determine the mechanism of action of this condition as a prerequisite to seeking an effective treatment. Published work suggest a role for the Mast Cells and/or Ion Channels and/or Genetics as playing a key role. In addition, suggestions will be presented for new areas of research to be investigated. These include non-canonical DNA structures as a target for chemical binding. The role of the microbiota in modifying chemical activity will be discussed. Histopathological approaches will be suggested. In particular, it will be proposed that just as there are characteristic features of different lung pathologies, so, too, perhaps, there is a unique presentation at the WSI level that, together with AI analysis, might provide important clues as to the etiology and pathological mechanism of MCS.  Attendees are invited to contribute their expertise to help solve this problematic puzzle of pathology.

References:
The Leifer Institute for Molecular and Digital Pathology www.limdp.org. Click on MCS.

Miller, C.S. et al Env Sci Europe 33:129 (2021)
Wu et al Nature Review Genetics   January 30, 2023
Molot, J. et al  Reviews on Environmental Health 37(4), 509-530 (2022)

Upcoming Conferences;

  1. Emirates Pathology, Digital Pathology & Cancer Conference
    More Details: https://pathology.universeconferences.com/
  2. World Digital Pathology & AI UCGCongress
    More Details: https://digitalpathology.ucgconferences.com/  

Related Articles

Back to top button